Developer docs
API playgroundTry for free, no card

Search company profiles

Neomorph

Full company profile

uuid0000msu

Namestring
Neomorph
Legal namestring
Neomorph, Inc.
Websiteurl
neomorph.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Neomorph, Inc. is a privately held, clinical-stage biotechnology company founded in 2020 and headquartered in San Diego, California. The company engineers molecular glue degraders — small molecules that induce targeted protein degradation by creating neomorphic protein-protein interactions between E3 ubiquitin ligases and disease-causing neo-substrates — to address proteins historically considered undruggable by conventional small-molecule approaches. Neomorph's lead wholly-owned asset, NEO-811, is an oral molecular glue degrader designed to degrade ARNT (HIF-1β) and is currently in a first-in-human Phase 1/2 clinical trial in patients with locally advanced or metastatic non-resectable clear cell renal cell carcinoma.

The company's core technology is a next-generation molecular glue discovery platform that integrates a proprietary E3 ubiquitin ligase database spanning hundreds of ligases beyond the industry-standard cereblon, multiple novel degrons beyond the canonical G-loop motif, proprietary glue libraries (including DNA-Encoded Library screening capabilities), world-class structural biology via X-ray crystallography and cryo-EM, and proprietary AI/ML algorithms for predictive interface compatibility and de novo glue design. The company was founded by scientific founders Eric Fischer, Benjamin Ebert, and Scott Armstrong — co-authors of the foundational 2014 Nature and Science papers that defined the cereblon molecular glue field — alongside President and CEO Philip Chamberlain, with former Celgene Chairman/CEO Robert J. Hugin serving as Chairman of the Board.

Neomorph monetizes through multi-year collaboration and licensing agreements with global Big Pharma partners rather than through product sales, with three active deals (AbbVie, Novo Nordisk, Biogen) carrying combined potential value approaching $5 billion and individual deals reported at up to $1.46–$1.64 billion each in upfront payments, R&D funding, development and commercialization milestones, and tiered royalties. The company has raised over $200 million in private venture capital within the six months preceding May 2026, including a $100 million Series B led by Deerfield Management in April 2026, and is expanding operations into a new 80,000-square-foot Class A laboratory facility in Sorrento Mesa, San Diego, with full transition expected in 2026.

Short descriptiontext

Neomorph is a San Diego-based clinical-stage biotech founded in 2020 that engineers molecular glue degraders — small molecules inducing targeted protein degradation via E3 ligases — to address historically undruggable disease-causing proteins, serving global Big Pharma partners (AbbVie, Novo Nordisk, Biogen) through collaboration and licensing deals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular glue degraders, targeted protein degradation, drug discovery platform, protein degradation therapeutics, biotech licensing
Industry4 codes
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Targeted Protein Degradation Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharma Partnership and Licensing Income
TypeLicensing Royalties
Description

Pre-revenue from product sales; revenue derived from multi-year collaboration and licensing agreements with Big Pharma (AbbVie, Novo Nordisk, Biogen), with combined potential value approaching $5 billion. Typical deal economics include upfront payments, ongoing R&D funding, development and commercialization milestone payments, and tiered royalties on future sales. Three active Big Pharma collaborations are reported at up to $1.46–$1.64 billion each.

businessofsandiego.substack.com
2Venture Capital Financing (Non-Revenue Capital)
TypeManaged Services
Description

Equity capital from venture financing rounds (e.g., $100 million Series B closed in April 2026 led by Deerfield Management with participation from Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, and Binney Street Capital of Dana-Farber Cancer Institute) used to fund clinical development and platform expansion rather than recognized as operating revenue.

financialpost.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Neomorph engineers molecular glue degraders — small molecules that induce targeted degradation of disease-causing proteins by creating new (neomorphic) protein-protein interactions with E3 ubiquitin ligases. The company operates a proprietary discovery platform combining an expansive E3 ligase database, novel degron libraries, proprietary glue libraries with DEL screening, structural biology, and AI/ML-driven rational design. Its lead asset NEO-811 is in a Phase 1/2 trial for clear cell renal cell carcinoma, and Neomorph monetizes its platform through multi-year collaboration and licensing agreements with Big Pharma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Targeted protein degradation market projected to grow from $5.95B (2025) to $12.44B (2034) — the addressable market for Neomorph's molecular glue modality.
+2 more records
Product and service4 records
1NEO-811
CategoryClinical-stage drug candidate
Description

A potent, selective, orally bioavailable molecular glue degrader designed to induce targeted degradation of ARNT (HIF-1β), blocking HIF signaling in clear cell renal cell carcinoma (ccRCC). Currently in a first-in-human Phase 1/2 clinical trial as monotherapy in patients with locally advanced or metastatic non-resectable ccRCC. Wholly owned by Neomorph.

2Molecular Glue Discovery Platform
CategoryDrug discovery platform
Description

Neomorph's next-generation, rational-design drug discovery platform for molecular glue degraders. Features the world's largest proprietary molecular glue target space with multiple novel degrons, unique glue libraries, an expansive portfolio of E3 ubiquitin ligases beyond cereblon, and proprietary AI/ML capability for rational prospective drug discovery. Licensed to Big Pharma partners for co-development of candidates.

3Undisclosed Solid Tumors Program
CategoryPipeline program (undisclosed)
Description

Undisclosed molecular glue degrader program targeting solid tumors, positioned in Neomorph's pipeline between discovery and IND-enabling stages.

4Early-Stage Pipeline Programs (Multiple Indications)
CategoryPipeline program (discovery stage)
Description

Discovery-stage molecular glue degrader programs being explored across multiple indications (oncology, immunology, neurodegeneration, virology, cardiometabolic, and rare disease) as part of Neomorph's broader pipeline, including defined targets in oncology/immunology and neurology.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Multi-year collaboration and licensing partnership for molecular glue degraders, publicly reported at up to $1.64 billion in deal value. The partnership is referenced alongside AbbVie's broader AI and biotech deal-making strategy (e.g., BigHat Biosciences, Capstan Therapeutics), positioning Neomorph as a strategic platform partner for AbbVie in targeted protein degradation. Listed as a partner on Neomorph's website.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Multi-year collaboration and licensing partnership for molecular glue degraders. Part of combined partnership potential value approaching $5 billion disclosed alongside AbbVie and Biogen. Listed as a partner on Neomorph's website, supporting Neomorph's platform reach into cardiometabolic and rare disease indications in Novo Nordisk's therapeutic focus.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Multi-year collaboration and licensing partnership for molecular glue degraders. Part of combined partnership potential value approaching $5 billion disclosed alongside AbbVie and Novo Nordisk. Listed as a partner on Neomorph's website, providing Neomorph with a partner in neurology indications aligned with Biogen's therapeutic focus.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Proxygen is a discovery-stage TPD company developing molecular glue degraders using a proprietary screening platform including yeast- and mammalian-cell based glue discovery. Directly comparable to Neomorph in glue discovery platform technology, with multiple Big Pharma collaborations.

TypeDirect peer
Description

Kymera is a clinical-stage TPD biotech developing heterobifunctional degraders and molecular glues, with active Sanofi partnership. Directly comparable to Neomorph in TPD platform development, oncology/inflammation focus, and pharma collaboration strategy.

TypeDirect peer
Description

BioTheryX develops targeted protein degraders (PHM) for hematological malignancies, including IMiD-based approaches. Comparable to Neomorph in TPD modality with cereblon-modulator expertise, and similar clinical-stage development profile.

TypeDirect peer
Description

C4 Therapeutics develops degronimid-based molecular glue degraders (e.g., cemsidomide) with active partnerships including Biogen and Merck KGaA/Roche. Closely comparable to Neomorph in glues with novel ligase binding modes and multi-program Big Pharma collaborations.

TypeBroad incumbent
Description

Novartis is a major pharma with active TPD and degrader research programs across oncology and other therapeutic areas. Comparable as a broad incumbent in protein degradation with the capital and commercial reach to in-license or acquire molecular glue platforms like Neomorph's.

TypeDirect peer
Description

Foghorn develops chromatin-based cancer therapies including a degrader platform targeting chromatin regulatory complexes. Comparable to Neomorph in protein degradation for oncology, with a platform approach and clinical-stage pipeline.

TypeDirect peer
Description

Amphista is a clinical-stage TPD biotech developing bifunctional and molecular glue degraders with active Bristol Myers Squibb partnership. Comparable to Neomorph in non-cereblon ligase targeting, protein degradation modality, and Big Pharma partnership structure.

8Bristol Myers Squibb
TypeBroad incumbent
Description

Bristol Myers Squibb is a major pharma with extensive CELMoD (cereblon modulator) franchise (lenalidomide/pomalidomide-derived degraders) via Celgene acquisition and Amphista partnership. Comparable as a broad incumbent in protein degradation with both internal pipeline and external platform partnership strategy that mirrors Neomorph's BD motion.

TypeDirect peer
Description

Monte Rosa develops molecular glue degraders for immunology and oncology indications using a quaternary structure-based platform and AI-enabled design. Directly comparable to Neomorph in glue-based TPD, AI-driven discovery, and clinical-stage pipeline focus.

TypeDirect peer
Description

Arvinas is a clinical-stage biotech pioneering targeted protein degradation via PROTACs and molecular glue degraders (e.g., vepdegestrant with Pfizer). Directly comparable to Neomorph in TPD modality, both cereblon- and non-cereblon-based degrader development, and BD-led Big Pharma partnership model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neomorph

Targeted Protein Degradation Therapeuticsneomorph.com

Neomorph is a San Diego-based clinical-stage biotech founded in 2020 that engineers molecular glue degraders — small molecules inducing targeted protein degradation via E3 ligases — to address historically undruggable disease-causing proteins, serving global Big Pharma partners (AbbVie, Novo Nordisk, Biogen) through collaboration and licensing deals.

What Neomorph does

Neomorph, Inc. is a privately held, clinical-stage biotechnology company founded in 2020 and headquartered in San Diego, California. The company engineers molecular glue degraders — small molecules that induce targeted protein degradation by creating neomorphic protein-protein interactions between E3 ubiquitin ligases and disease-causing neo-substrates — to address proteins historically considered undruggable by conventional small-molecule approaches. Neomorph's lead wholly-owned asset, NEO-811, is an oral molecular glue degrader designed to degrade ARNT (HIF-1β) and is currently in a first-in-human Phase 1/2 clinical trial in patients with locally advanced or metastatic non-resectable clear cell renal cell carcinoma.

The company's core technology is a next-generation molecular glue discovery platform that integrates a proprietary E3 ubiquitin ligase database spanning hundreds of ligases beyond the industry-standard cereblon, multiple novel degrons beyond the canonical G-loop motif, proprietary glue libraries (including DNA-Encoded Library screening capabilities), world-class structural biology via X-ray crystallography and cryo-EM, and proprietary AI/ML algorithms for predictive interface compatibility and de novo glue design. The company was founded by scientific founders Eric Fischer, Benjamin Ebert, and Scott Armstrong — co-authors of the foundational 2014 Nature and Science papers that defined the cereblon molecular glue field — alongside President and CEO Philip Chamberlain, with former Celgene Chairman/CEO Robert J. Hugin serving as Chairman of the Board.

Neomorph monetizes through multi-year collaboration and licensing agreements with global Big Pharma partners rather than through product sales, with three active deals (AbbVie, Novo Nordisk, Biogen) carrying combined potential value approaching $5 billion and individual deals reported at up to $1.46–$1.64 billion each in upfront payments, R&D funding, development and commercialization milestones, and tiered royalties. The company has raised over $200 million in private venture capital within the six months preceding May 2026, including a $100 million Series B led by Deerfield Management in April 2026, and is expanding operations into a new 80,000-square-foot Class A laboratory facility in Sorrento Mesa, San Diego, with full transition expected in 2026.

Neomorph firmographics

Firmographics
Name
Neomorph
Legal name
Neomorph, Inc.
Website
https://neomorph.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Neomorph is a San Diego-based clinical-stage biotech founded in 2020 that engineers molecular glue degraders — small molecules inducing targeted protein degradation via E3 ligases — to address historically undruggable disease-causing proteins, serving global Big Pharma partners (AbbVie, Novo Nordisk, Biogen) through collaboration and licensing deals.
Ownership category
akta.pro rank

Neomorph industry classification

Industry
Product category
Targeted Protein Degradation Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Molecular glue degraders
  • Targeted protein degradation
  • Drug discovery platform
  • Protein degradation therapeutics
  • Biotech licensing

Where Neomorph is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Neomorph business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Others

Revenue model

  1. Pharma Partnership and Licensing Income: Pre-revenue from product sales; revenue derived from multi-year collaboration and licensing agreements with Big Pharma (AbbVie, Novo Nordisk, Biogen), with combined potential value approaching $5 billion. Typical deal economics include upfront payments, ongoing R&D funding, development and commercialization milestone payments, and tiered royalties on future sales. Three active Big Pharma collaborations are reported at up to $1.46–$1.64 billion each.
  2. Venture Capital Financing (Non-Revenue Capital): Equity capital from venture financing rounds (e.g., $100 million Series B closed in April 2026 led by Deerfield Management with participation from Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, and Binney Street Capital of Dana-Farber Cancer Institute) used to fund clinical development and platform expansion rather than recognized as operating revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Neomorph product offering

Product offering

Core offering

Neomorph engineers molecular glue degraders — small molecules that induce targeted degradation of disease-causing proteins by creating new (neomorphic) protein-protein interactions with E3 ubiquitin ligases. The company operates a proprietary discovery platform combining an expansive E3 ligase database, novel degron libraries, proprietary glue libraries with DEL screening, structural biology, and AI/ML-driven rational design. Its lead asset NEO-811 is in a Phase 1/2 trial for clear cell renal cell carcinoma, and Neomorph monetizes its platform through multi-year collaboration and licensing agreements with Big Pharma.

Differentiator

Problem solved

Functional benefit

Products and services

  • NEO-811 A potent, selective, orally bioavailable molecular glue degrader designed to induce targeted degradation of ARNT (HIF-1β), blocking HIF signaling in clear cell renal cell carcinoma (ccRCC). Currently in a first-in-human Phase 1/2 clinical trial as monotherapy in patients with locally advanced or metastatic non-resectable ccRCC. Wholly owned by Neomorph.
  • Molecular Glue Discovery Platform Neomorph's next-generation, rational-design drug discovery platform for molecular glue degraders. Features the world's largest proprietary molecular glue target space with multiple novel degrons, unique glue libraries, an expansive portfolio of E3 ubiquitin ligases beyond cereblon, and proprietary AI/ML capability for rational prospective drug discovery. Licensed to Big Pharma partners for co-development of candidates.
  • Undisclosed Solid Tumors Program Undisclosed molecular glue degrader program targeting solid tumors, positioned in Neomorph's pipeline between discovery and IND-enabling stages.
  • Early-Stage Pipeline Programs (Multiple Indications) Discovery-stage molecular glue degrader programs being explored across multiple indications (oncology, immunology, neurodegeneration, virology, cardiometabolic, and rare disease) as part of Neomorph's broader pipeline, including defined targets in oncology/immunology and neurology.

Quantifiable outcome

  • Targeted protein degradation market projected to grow from $5.95B (2025) to $12.44B (2034) — the addressable market for Neomorph's molecular glue modality.
  • +2 more outcomes

Companies that use Neomorph

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Neomorph technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Neomorph partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship.

  • AbbVieflagshipStrategic or Co-development Partner · 1 January 2025Multi-year collaboration and licensing partnership for molecular glue degraders, publicly reported at up to $1.64 billion in deal value. The partnership is referenced alongside AbbVie's broader AI and biotech deal-making strategy (e.g., BigHat Biosciences, Capstan Therapeutics), positioning Neomorph as a strategic platform partner for AbbVie in targeted protein degradation. Listed as a partner on Neomorph's website.
  • Novo NordiskflagshipStrategic or Co-development PartnerMulti-year collaboration and licensing partnership for molecular glue degraders. Part of combined partnership potential value approaching $5 billion disclosed alongside AbbVie and Biogen. Listed as a partner on Neomorph's website, supporting Neomorph's platform reach into cardiometabolic and rare disease indications in Novo Nordisk's therapeutic focus.
  • BiogenflagshipStrategic or Co-development PartnerMulti-year collaboration and licensing partnership for molecular glue degraders. Part of combined partnership potential value approaching $5 billion disclosed alongside AbbVie and Novo Nordisk. Listed as a partner on Neomorph's website, providing Neomorph with a partner in neurology indications aligned with Biogen's therapeutic focus.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Neomorph competitors and assessment

Company assessment

Direct peers

  • Proxygen: Proxygen is a discovery-stage TPD company developing molecular glue degraders using a proprietary screening platform including yeast- and mammalian-cell based glue discovery. Directly comparable to Neomorph in glue discovery platform technology, with multiple Big Pharma collaborations.
  • Kymera Therapeutics: Kymera is a clinical-stage TPD biotech developing heterobifunctional degraders and molecular glues, with active Sanofi partnership. Directly comparable to Neomorph in TPD platform development, oncology/inflammation focus, and pharma collaboration strategy.
  • BioTheryX: BioTheryX develops targeted protein degraders (PHM) for hematological malignancies, including IMiD-based approaches. Comparable to Neomorph in TPD modality with cereblon-modulator expertise, and similar clinical-stage development profile.
  • C4 Therapeutics: C4 Therapeutics develops degronimid-based molecular glue degraders (e.g., cemsidomide) with active partnerships including Biogen and Merck KGaA/Roche. Closely comparable to Neomorph in glues with novel ligase binding modes and multi-program Big Pharma collaborations.
  • Foghorn Therapeutics: Foghorn develops chromatin-based cancer therapies including a degrader platform targeting chromatin regulatory complexes. Comparable to Neomorph in protein degradation for oncology, with a platform approach and clinical-stage pipeline.
  • Amphista Therapeutics: Amphista is a clinical-stage TPD biotech developing bifunctional and molecular glue degraders with active Bristol Myers Squibb partnership. Comparable to Neomorph in non-cereblon ligase targeting, protein degradation modality, and Big Pharma partnership structure.
  • Monte Rosa Therapeutics: Monte Rosa develops molecular glue degraders for immunology and oncology indications using a quaternary structure-based platform and AI-enabled design. Directly comparable to Neomorph in glue-based TPD, AI-driven discovery, and clinical-stage pipeline focus.
  • Arvinas: Arvinas is a clinical-stage biotech pioneering targeted protein degradation via PROTACs and molecular glue degraders (e.g., vepdegestrant with Pfizer). Directly comparable to Neomorph in TPD modality, both cereblon- and non-cereblon-based degrader development, and BD-led Big Pharma partnership model.

Broad incumbents

  • Novartis: Novartis is a major pharma with active TPD and degrader research programs across oncology and other therapeutic areas. Comparable as a broad incumbent in protein degradation with the capital and commercial reach to in-license or acquire molecular glue platforms like Neomorph's.
  • Bristol Myers Squibb: Bristol Myers Squibb is a major pharma with extensive CELMoD (cereblon modulator) franchise (lenalidomide/pomalidomide-derived degraders) via Celgene acquisition and Amphista partnership. Comparable as a broad incumbent in protein degradation with both internal pipeline and external platform partnership strategy that mirrors Neomorph's BD motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Neomorph social profiles

Digital presence

Neomorph financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neomorph leadership team

Management profile

Number of profiles

Profiles1 record

Neomorph funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neomorph M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neomorph

What does Neomorph do?

Neomorph engineers molecular glue degraders — small molecules that induce targeted degradation of disease-causing proteins by creating new (neomorphic) protein-protein interactions with E3 ubiquitin ligases. The company operates a proprietary discovery platform combining an expansive E3 ligase database, novel degron libraries, proprietary glue libraries with DEL screening, structural biology, and AI/ML-driven rational design. Its lead asset NEO-811 is in a Phase 1/2 trial for clear cell renal cell carcinoma, and Neomorph monetizes its platform through multi-year collaboration and licensing agreements with Big Pharma.

Is Neomorph a public or private company?

Neomorph is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neomorph founded?

Neomorph was founded in 2020. It employs 51 to 100 people.

Where is Neomorph based?

Neomorph is headquartered in San Diego, United States, in the North America region.

How does Neomorph make money?

Two revenue lines are on record. Pharma Partnership and Licensing Income is the primary driver. The others are venture Capital Financing (Non-Revenue Capital).

Who are Neomorph's main competitors?

Direct peers on record are Proxygen, Kymera Therapeutics, BioTheryX, C4 Therapeutics, Foghorn Therapeutics, Amphista Therapeutics, Monte Rosa Therapeutics and Arvinas. Broad incumbents are Novartis and Bristol Myers Squibb.

Does Neomorph have an API?

No public API is recorded for Neomorph.

What industry is Neomorph in?

Neomorph's product category is Targeted Protein Degradation Therapeutics. Its primary akta.pro industry code is HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceOnes to watch: 4 biotechs with recent Series B raises (that are also hiring)Four biotech companies announced Series B financing rounds in 2024–2025 and are actively recruiting as they advance their pipelines: BreezeBio ($60M), City Therapeutics ($99.5M), Neomorph ($100M), and Ray Therapeutics ($125M), totaling approximately $384.5 million across the group. BreezeBio is advancing genetic medicines including a type 1 diabetes therapy with a Genentech partnership, City Therapeutics is developing RNAi medicines for blood clots and rare eye diseases with leadership from former Alnylam executives, Neomorph is progressing molecular glue degraders for kidney cancer and solid tumors with three active Big Pharma collaborations worth up to $1.46–$1.64 billion each, and Ray Therapeutics received FDA RMAT designation for its retinitis pigmentosa candidate RTx-015 alongside its $125M raise. The article, aimed at biopharma job seekers, lists specific open positions at each company.SubstackExclusive: Inside Neomorph’s Rise During a Tough Market for BiotechNeomorph, a San Diego-based biotech company, has raised over $200 million in private venture capital over the past six months and signed partnership agreements with a combined potential value approaching $5 billion with AbbVie, Novo Nordisk, and Biogen. The company is developing molecular glue therapies targeting cancer, immunology, and other diseases, with its lead candidate NEO-811 currently in a Phase 1/2 first-in-human clinical trial. To support its growth, Neomorph has signed a lease for an 80,000-square-foot Class A laboratory facility in Sorrento Mesa, expecting to fully transition into the space later this year.BioSpaceNeomorph Appoints Biopharma Leader Robert J. Hugin as Chairman of the BoardNeomorph appointed Bob Hugin, former Celgene CEO, as chairman of its board. He brings over 30 years of biopharma leadership, including roles at Celgene and PhRMA. Neomorph's molecular glue degrader platform targets undruggable proteins.MedCity NewsWindward Bio Secures $165M for Clinical Trials in Asthma, COPD & MoreWindward Bio raised $165 million in a crossover round led by OrbiMed to advance its TSLP-blocking antibody WIN378. The drug is in Phase 2/3 testing with Phase 3 expected to start in Q4, and a COPD trial is planned this quarter. The funding extends its cash runway to reach multiple clinical trial readouts within 12 months.BioWorldNEO-811 overcomes HIF resistance in renal cancerNeomorph Inc.'s NEO-811 is a molecular glue degrader that induces targeted degradation of ARNT, suppressing a signaling pathway implicated in clear cell renal cell carcinoma. Targeting ARNT offers a complementary strategy to broadly disrupt oncogenic HIF signaling in ccRCC.pharmaphorumBeeline raises $300m for BMS drugs, and other biofinancingsMultiple biopharma companies announced significant private financing rounds, with Beeline Medicines formally launching with a $300 million Series A funded by Bain Capital and a pipeline of immunology and inflammation drug candidates licensed from Bristol Myers Squibb. Oricell Therapeutics of Shanghai raised over $110 million in a pre-IPO round led by Vivo Capital and Qiming Venture Partners for its cell therapy pipeline targeting solid tumours and blood cancers, including Ori-C101 for liver cancer. Terremoto Biosciences secured $108 million Series C, Harbinger Health $100 million, Neomorph $100 million, Adcendo $75 million, and STORM Therapeutics $56 million to advance respective oncology and specialty drug development programmes.The Pharma LetterNeomorph secures $100M Series B to scale molecular glue degrader pipelineNeomorph closed a $100 million Series B led by Deerfield Management, with participation from Regeneron Ventures and others. The funds will support the Phase I/II trial of NEO-811 and advance a pipeline of molecular glue degraders against undruggable targets.BioWorldFinancings for April 14, 2026On April 14, 2026, biopharma and med-tech companies Hemab, Imagenebio, Lobe, Neomorph, Quiver, Seaport, and Sharp raised funds through public or private financings. The list includes these seven companies, with no further details provided.BioSpaceNeomorph to Highlight Progress in Targeted Protein Degradation Science at the American Association for Cancer Research Annual MeetingNeomorph will present NEO-811, a molecular glue degrader targeting ARNT (HIF-1β) for clear cell renal cell carcinoma, at the AACR Annual Meeting in San Diego. The drug is being evaluated as a monotherapy in a first-in-human Phase 1/2 trial for locally advanced or metastatic non-resectable ccRCC.BioSpaceNeomorph Announces Closing of $100 Million Series B FinancingNeomorph closed a $100 million Series B financing led by Deerfield Management, with participation from Regeneron Ventures and others. The funds will support the Phase 1/2 trial of NEO-811 for clear cell renal cell carcinoma and advance its molecular glue degrader pipeline.